Search research articles
Contact Us
Filters
Showing results (51-60 of 56) with videos related to
Page
of 6
Sort By:
You have reached the last page of results.
This site can display upto 56 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 15, 2016
A Phase I Dose-Escalation Study Evaluating the Safety Tolerability and Pharmacokinetics of CUDC-427, a Potent, Oral, Monovalent IAP Antagonist, in Patients with Refractory Solid Tumors
Anthony W Tolcher, Johanna C Bendell, Kyriakos P Papadopoulos, et al.
Cancer Chemotherapy and Pharmacology
|
March 18, 2014
A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors
Amita Patnaik, Patricia M LoRusso, Wells A Messersmith, et al.
Blood
|
July 15, 2004
Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes
Norman J Lacayo, Soheil Meshinchi, Paivi Kinnunen, et al.
Medrxiv : the Preprint Server for Health Sciences
|
June 27, 2020
Innate immune signaling in the olfactory epithelium reduces odorant receptor levels: modeling transient smell loss in COVID-19 patients
Steven Rodriguez, Luxiang Cao, Gregory T Rickenbacher, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology
|
July 31, 2012
Dogs are more sensitive to antagonists of inhibitor of apoptosis proteins than rats and humans: a translational toxicokinetic/toxicodynamic analysis
Harvey Wong, Nageshwar R Budha, Kristina West, et al.
Journal of Medicinal Chemistry
|
March 15, 2012
Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152)
John A Flygare, Maureen Beresini, Nageshwar Budha, et al.
Page
of 6
Search research articles
Search
Showing results (51-60 of 56) with videos related to
Sort By:
Page
of 6
You have reached the last page of results.
This site can display upto 56 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 15, 2016
A Phase I Dose-Escalation Study Evaluating the Safety Tolerability and Pharmacokinetics of CUDC-427, a Potent, Oral, Monovalent IAP Antagonist, in Patients with Refractory Solid Tumors
Anthony W Tolcher, Johanna C Bendell, Kyriakos P Papadopoulos, et al.
Cancer Chemotherapy and Pharmacology
|
March 18, 2014
A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors
Amita Patnaik, Patricia M LoRusso, Wells A Messersmith, et al.
Blood
|
July 15, 2004
Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes
Norman J Lacayo, Soheil Meshinchi, Paivi Kinnunen, et al.
Medrxiv : the Preprint Server for Health Sciences
|
June 27, 2020
Innate immune signaling in the olfactory epithelium reduces odorant receptor levels: modeling transient smell loss in COVID-19 patients
Steven Rodriguez, Luxiang Cao, Gregory T Rickenbacher, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology
|
July 31, 2012
Dogs are more sensitive to antagonists of inhibitor of apoptosis proteins than rats and humans: a translational toxicokinetic/toxicodynamic analysis
Harvey Wong, Nageshwar R Budha, Kristina West, et al.
Journal of Medicinal Chemistry
|
March 15, 2012
Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152)
John A Flygare, Maureen Beresini, Nageshwar Budha, et al.
Page
of 6